Literature DB >> 7961206

Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges.

R Dagan1, L Velghe, J L Rodda, K P Klugman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7961206     DOI： 10.1093/jac/34.1.175

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  24 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

Authors:  F Fitoussi; C Doit; K Benali; S Bonacorsi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 4.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.

Authors:  L Zerva; D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

6.  Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Domenech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04-02       Impact factor: 3.267

Review 7.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

8.  Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

Review 9.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

10.  Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis.

Authors:  Shin-Woo Kim; Joung Hwa Jin; Soo Jung Kang; Sook-In Jung; Yeon-Sook Kim; Choon-Kwan Kim; Hyuck Lee; Won Sup Oh; Sungmin Kim; Kyong Ran Peck; Jae-Hoon Song
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.